Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease

Lara C. Pullen, PhD  |  December 10, 2018

Many patients with rheumatoid arthritis (RA) experience clinical or subclinical lung involvement and approximately 10% will develop interstitial lung disease (ILD). RA with ILD resembles idiopathic pulmonary fibrosis, which has led scientists to question whether the two conditions have a similar underlying pathophysiology. The pathogenesis of idiopathic pulmonary fibrosis may be the result of abnormalities in surfactant secretion predisposition to cell senescence, as well as interference with ciliary clearance. Past research has found parallels in RA patients who frequently have shortened telomeres and patients with ILD who not only carry risk alleles for telomere shortening, but also have more accelerated telomere shortening.

Recently, scientists performed genome-wide association studies to identify common genetic variants that may contribute to the development of idiopathic pulmonary fibrosis. They identified a gain-of-function promoter variant in MUC5B (rs35705950) that accounts for approximately 30–35% of the genetic risk for the development of idiopathic pulmonary fibrosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The parallels between idiopathic pulmonary fibrosis and ILD have led Pierre-Antoine Juge, MD, a rheumatologist at Bichat-Claude Bernard Hospital, Paris, and colleagues to question whether this risk factor for idiopathic pulmonary fibrosis may also contribute to the risk of ILD among RA patients. In their latest research, they found the promoter variant in MUC5B (rs35705950) is not only associated with RA with complicating ILD, but is also specifically associated with evidence of unusual interstitial pneumonia on imaging. Their results were published on Oct. 20 in the New England Journal of Medicine.¹

The investigators first used a discovery population to compare patients with RA and ILD to unaffected controls. From this population, they determined the minor allele of the MUC5B promoter variant was associated with disease. They next analyzed a multi-ethnic case series and found the variant was significantly over-represented among patients with RA and ILD relative to unaffected controls. When researchers looked within the RA population, they found an association between the MUC5B promoter variant and an increased risk of ILD. However, they note the variant was not associated with RA diagnosis alone.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators found the effect of the promoter variant in ILD development for RA patients was similar in magnitude and direction to that observed for patients with idiopathic pulmonary fibrosis. Moreover, the relationship between the MUC5B promoter variant and RA with ILD appeared to be specific to the usual interstitial pneumonia (UIP) pattern as seen by high-resolution CT scan. Researchers also found TOLLIP rs5743890 and IVD rs2034650 may contribute to the risk of RA with ILD. All told, their findings suggest that RA with ILD is a complex genetic phenotype.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:ILDInterstitial Lung DiseaseMUC5BRheumatoid Arthritis (RA)

Related Articles

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    Insights into Interstitial Lung Disease in Rheumatoid Arthritis Patients

    October 18, 2019

    MADRID—Rheumatoid arthritis (RA) is among the most common autoimmune diseases in the U.S., affecting approximately 1.3 million U.S. adults.1 Although tremendous treatment advances have been made in recent years, one extra-articular manifestation of RA that continues to pose a challenge with regard to detection and management is interstitial lung disease (ILD). At the 2019 European…

    Catch Your Breath: Insights into ILD in RA Patients

    September 12, 2019

    Detecting interstitial lung disease in RA patients can be challenging. But evaluating risk factors and the use of imaging can help clinicians identify and manage this condition in patients…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences